DR. MARY JEANNE KREEK, MD
Osteopathic Medicine in New York, NY

6335168, Jan 1, 2002

Jul 9, 1999

09/351198

Mary Jeanne Kreek - New York NY
Karl Steven LaForge - New York NY
Lei Yu - Cincinnati OH
Jay A. Tischfield - Carmel IN

The Rockefeller University - New York NY
The Advanced Research and Technology Institute, Inc. - Bloomington IN

C12Q 168

435 6, 536 235

Provided herein are variant alleles of a gene encoding a mu opioid receptor, along with cloning vectors for replicating such variant alleles, expressing vectors for expressing the variant alleles to produce variant mu opioid receptors, and antibodies to such variant receptors. Also disclosed are binding characteristics of such variant receptors regarding binding to opioid ligands, and the using of such binding characteristics to diagnose a subjects susceptibility to pain, susceptibility to an addictive disease, selecting an appropriate pain reliever along with a therapeutically effective amount of the reliever to administer to a subject suffering from pain. In addition, diagnostic methods for diagnosing a disease or disorder such as infertility, constipation, diarrhea, decreased immune response relative to a standard, and decreased ability to withstand stress relative to a standard, along with commercial kits for diagnosing such diseases or disorders. Furthermore, the invention is also directed to identification of targeted prevention methods, early therapeutic intervention, and improved treatment of opioid addiction, infertility, constipation, diarrhea, impaired immune responsiveness, and stress.

6337207, Jan 8, 2002

Jul 10, 1998

09/113426

Mary Jeanne Kreek - New York NY
Karl Steven LaForge - New York NY
Lei Yu - Cincinnati OH
Jay A. Tischfield - Carmel IN

The Rockefeller University - New York NY
The Advanced Research and Technology Institute, Inc. - Bloomington IN

C12N 1563

4353201, 536 235, 435325

Provided herein are variant alleles of a gene encoding a mu opioid receptor, along with cloning vectors for replicating such variant alleles, expressing vectors for expressing the variant alleles to produce variant mu opioid receptors, and antibodies to such variant receptors. Also disclosed are binding characteristics of such variant receptors regarding binding to opioid ligands, and the using of such binding characteristics to diagnose a subjects susceptibility to pain, susceptibility to an addictive disease, selecting an appropriate pain reliever along with a therapeutically effective amount of the reliever to administer to a subject suffering from pain. In addition, diagnostic methods for diagnosing a disease or disorder such as infertility, constipation, diarrhea, decreased immune response relative to a standard, and decreased ability to withstand stress relative to a standard, along with commercial kits for diagnosing such diseases or disorders.

7071315, Jul 4, 2006

Jun 18, 2001

09/883839

Mary Jeanne Kreek - New York NY, US
Karl Steven LaForge - New York NY, US

The Rockefeller University - New York NY

C07H 21/04

536 231, 435 691, 4353201, 4352523, 435455, 435471, 435325, 536 235

Provided herein are variant alleles of a gene encoding a mu opioid receptor, along with cloning vectors for replicating such variant alleles, expressing vectors for expressing the variant alleles to produce variant mu opioid receptors, and antibodies to such variant receptors. Also disclosed are binding characteristics of such variant receptors regarding binding to opioid ligands, and the using of such binding characteristics to diagnose a subjects susceptibility to pain, susceptibility to an addictive disease, selecting an appropriate pain reliever along with a therapeutically effective amount of the reliever to administer to a subject suffering from pain. In addition, diagnostic methods for diagnosing a disease or disorder such as infertility, constipation, diarrhea, decreased immune response relative to a standard, and decreased ability to withstand stress relative to a standard, along with commercial kits for diagnosing such diseases or disorders. Furthermore, the invention is also directed to identification of targeted prevention methods, early therapeutic intervention, and improved treatment of opioid addiction, infertility, constipation, diarrhea, impaired immune responsiveness, and stress.

4769372, Sep 6, 1988

Jun 18, 1986

6/875560

Mary J. Kreek - New York NY

The Rockefeller University - New York NY

A61K 3144

514282

A method of treating patients in chronic pain or suffering from chronic cough over a prolonged period to provide systemic analgesia or central antitussive effect while simultaneously avoiding the onset of intestinal hypomotility. The method includes the oral administration to the patient of dosage units comprising in combination opioid analgesics or antitussives and selected opioid antagonists which are substantially devoid of systemic antagonist activity when administered orally.

5817628, Oct 6, 1998

Dec 2, 1992

7/984469

Mary Jeanne Kreek - New York NY

The Rockefeller University - New York NY

A61K 3800, C07K 708

514 13

This invention provides a method of suppressing the cytotoxic activity of mammalian Natural Killer (NK) cells. The method of this invention comprises administering to an individual in need of treatment a polypeptide comprising the amino acid sequence corresponding to dynorphin A or a dynorphin A analog, including amidated analogs, in an amount sufficient to suppress the cytotoxic activity of NK cells. This invention is particularly useful for those individuals undergoing gene therapy who are to be infected with a viral or viroid vector containing a therapeutic gene. This invention is also useful to aid recipients of transplanted tissue and for individuals suffering from autoimmune diseases.

4785000, Nov 15, 1988

Nov 16, 1987

7/121784

Mary J. Kreek - New York NY
Jack Fishman - New York NY

The Rockefeller University - New York NY

A61K 3122, A61K 3144

514282

A method of treating patients in chronic pain or suffering from chronic cough over a prolonged period to provide systemic analgesia or central antitussive effect while simultaneously avoiding the onset of intestinal hypomotility. The method includes the oral administration to the patient of dosage units comprising in combination opioid analgesics or antitussives and selected opioid antagonists which are substantially devoid of systemic antagonist activity when administered orally.

7033759, Apr 25, 2006

Jul 13, 2001

09/904584

Mary Jeanne Kreek - New York NY, US
Vadim Yuferov - New York NY, US
Karl Steven LaForge - New York NY, US

The Rockfeller University - New York NY

C12Q 1/68, C07H 21/04

435 6, 435 691, 435 912, 4352523, 4353201, 536 235, 536 2433

Provided herein are variant alleles of a gene encoding a kappa opioid receptor, along with cloning vectors for replicating such variant alleles, and expressing vectors for expressing the variant alleles to produce variant kappa opioid receptors.

4987136, Jan 22, 1991

Feb 12, 1986

6/828533

Mary J. Kreek - New York NY
Jack Fishman - New York NY

The Rockefeller University - New York NY

A61K 3144

514282

Method for controlling gastrointestinal dysmotility in humans by administration of opioid antagonists.